Who are Etoricoxib + Betamethasone fixed dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fixed Dose Etoricoxib + Betamethasone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etoricoxib-betamethasone-fixed-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Etoricoxib + Betamethasone fixed dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Etoricoxib + Betamethasone fixed dose (Etoricoxib + Betamethasone fixed dose) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: COX-2 inhibitor + corticosteroid combination. Area: Rheumatology / Inflammatory diseases.

phase 3 COX-2 inhibitor + corticosteroid combination COX-2 enzyme; glucocorticoid receptor Rheumatology / Inflammatory diseases Small molecule Live · refreshed every 30 min

Target snapshot

Etoricoxib + Betamethasone fixed dose (Etoricoxib + Betamethasone fixed dose) — Laboratorios Silanes S.A. de C.V.. Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while betamethasone provides additional anti-inflammatory and immunosuppressive effects via glucocorticoid receptor activation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Etoricoxib + Betamethasone fixed dose TARGET	Etoricoxib + Betamethasone fixed dose	Laboratorios Silanes S.A. de C.V.	phase 3	COX-2 inhibitor + corticosteroid combination	COX-2 enzyme; glucocorticoid receptor
Fixed Dose Etoricoxib + Betamethasone	Fixed Dose Etoricoxib + Betamethasone	Laboratorios Silanes S.A. de C.V.	phase 3	COX-2 inhibitor + corticosteroid combination	COX-2 and glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (COX-2 inhibitor + corticosteroid combination class)

Laboratorios Silanes S.A. de C.V. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Etoricoxib + Betamethasone fixed dose — Competitive Intelligence Brief. https://druglandscape.com/ci/etoricoxib-betamethasone-fixed-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab